Morgan Stanley Keeps Their Buy Rating on Tuas Ltd. (TUA)
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
According to TipRanks, Bales is a 2-star analyst with an average return of 0.4% and a 40.96% success rate. Bales covers the Consumer Cyclical sector, focusing on stocks such as Collins Foods , Corporate Travel Management Limited, and Temple & Webster Group Ltd.
In addition to Morgan Stanley, Tuas Ltd. also received a Buy from Citi's William Park CPA in a report issued on July 29. However, on July 28, TR | OpenAI – 4o initiated coverage with a Hold rating on Tuas Ltd. (ASX: TUA).
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Industrials, Banks to Drive M&A: Morgan Stanley's Miles
Dealmakers are raking in billions in M&A despite lingering fears about trade wars and geopolitics. Transaction values are up almost a fifth this year at $2.2 trillion, according to data compiled by Bloomberg. The latest boost to activity comes from almost $100 billion worth of announced deals in the US industrials sector. Tom Miles, Global Co-Head of M&A at Morgan Stanley joined Wall Street Beat on Bloomberg Open Interest to identify where he anticipates the most M&A action. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
27 minutes ago
- Yahoo
Why Morgan Stanley Upgraded This Biotech Stock to a Buy
Sitting at a market cap of $6.8 billion, Ionis Pharmaceuticals (IONS) is a U.S.-based biotech company that develops RNA-targeted therapeutics to treat diseases caused by genetic or biochemical dysregulation. Ionis has many approved products in the market, most in collaboration with large pharmaceutical companies. However, it independently launched its sole product, Tryngolza, in December of last year. The drug had a blockbuster performance following its commercial launch. IONS stock has surged 21.5% year-to-date, outperforming the market. Based on the biotech's strong second-quarter results, Morgan Stanley analyst Michael Ulz upgraded the stock to a "Buy" with about 45% upside potential, based on the target price of $62. More News from Barchart Find Winning Momentum Trades With This Moving Average Stock Screener Tariffs, Earnings and Other Can't Miss Items this Week Dear Nvidia Stock Fans, Mark Your Calendars for August 27 Get exclusive insights with the FREE Barchart Brief newsletter. Subscribe now for quick, incisive midday market analysis you won't find anywhere else. Ulz cited a combination of strong operational performance and promising future catalysts as reasons for his bullish stance on Ionis. Let's take a look at what those drivers are, and whether Ionis stock is truly a 'Buy' now. Why Did Morgan Stanley Upgrade IONS Stock? According to Michael Ulz, the launch of Tryngolza was the standout factor in Ionis' second quarter earnings, exceeding not only Wall Street's expectations but also initial internal sales forecasts. Its robust commercial debut shows Ionis' management's strong execution capabilities and solidifies investor confidence in the company's strategic direction. Tryngolza (olezarsen) is used to treat familial chylomicronemia syndrome (FCS), a rare and life-threatening genetic lipid disorder in adults, in combination with diet. It was the drug's second full quarter on the market, with net product sales of $19 million in Q2. Management emphasized in the Q2 earnings call that physicians are prescribing it to a large number of patients, indicating increased confidence in the drug. Furthermore, approximately 60% of patients are covered by commercial insurance and 40% by government programs, with more than 90% paying no out-of-pocket costs, contributing to the drug's success. Crucially, with a positive opinion from the European CHMP (Committee for Medicinal Products for Human Use), Ionis is planning to expand Tryngolza's reach throughout Europe. This will lay the groundwork for significant international expansion. The company also earned a royalty revenue of $70 million from the following products, among others: Spinraza (nusinersen) — for spinal muscular atrophy in partnership with Biogen (BIIB) Wainua (eplontersen) — for ATTRv PN, co-commercialized with AstraZeneca (AZN) Total revenue in the second quarter increased by an impressive 100.8% year-on-year to $452 million. The company also reported a profit of $0.70 per share, up from a loss of $0.45 per share in the year-ago quarter. Morgan Stanley's Ulz also mentioned many upcoming events that could boost the stock, including the anticipated Phase 3 readouts for severe hypertriglyceridemia (SHTG) and other pipeline updates scheduled for 2026. Furthermore, early feedback from key opinion leaders on the upcoming Phase 3 CORE/CORE2 data for Olezarsen to treat patients with sHTG has been overwhelmingly positive, adding to the sense of optimism. The company expects topline data from the trial in September of this year. Notably, Ionis has an extensive late-stage pipeline, with many in Phase 2-3 clinical development. Donidalorsen is expected to be approved in August for hereditary angioedema (HAE), a rare but well-known genetic condition that causes painful swelling episodes. Management believes Donidalorsen has the potential to significantly broaden the company's footprint, as up to 20% of HAE patients switch prophylactic therapies each year, indicating dissatisfaction with current options. Furthermore, ION582 is beginning a Phase 3 trial to determine its efficacy for Angelman syndrome (AS), a serious and rare neurodevelopmental disorder. With a successful drug launch under its belt and multiple potential catalysts on the horizon, Morgan Stanley believes Ionis is well-positioned for continued growth. Management is also confident that the company's current momentum will lead to long-term revenue growth and positive cash flow. For the full year, Ionis expects revenue to increase by 17% to 20%, to $825 million to $850 million, while analysts predict $869.6 million in revenue. What Are Other Analysts Saying About IONS Stock? Aside from Morgan Stanley, Oppenheimer, Needham, Raymond James, and H.C. Wainwright analysts also maintain a 'Buy' rating for IONS stock. Furthermore, H.C. Wainwright has raised the target price to $65 from $50. Separately, Wells Fargo analyst Yanan Zhu maintained a 'Buy' rating and a target price of $77 for IONS after the company's strong second-quarter performance, which the firm says reflected both top-line momentum and operational discipline. Zhu also highlighted the company's strategic execution, specifically the successful launch of Tryngolza. Looking ahead, Zhu expects additional upside from several key catalysts, including upcoming pivotal trial readouts and potential regulatory milestones. These developments could further strengthen the company's pipeline and unlock long-term value for shareholders. Overall, on Wall Street, IONS remains a 'Moderate Buy.' Of the 23 analysts covering the stock, 15 rate it a 'Strong Buy,' two say it is a 'Moderate Buy,' five rate it a 'Hold,' and one suggests a 'Strong Sell.' The average target price of $57.77 suggests an upside potential of 35% from current levels. Additionally, the Street-high estimate of $83 suggests the stock has an upside potential of 93% over the next 12 months. With successful products and a robust pipeline approaching key milestones, Ionis appears to be on track to become a multi-product, multibillion-dollar biotech leader, which explains analysts' optimism for the stock. Ionis is developing a long-term, growth-oriented business model capable of delivering transformational therapies to patients while providing strong returns to investors, making it a compelling biotech stock for the long haul. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on
Bloomberg
37 minutes ago
- Bloomberg
Industrials, Banks to Drive M&A: Morgan Stanley's Miles (Video)
00:00 Time now for the Wall Street beat dealmakers. They are raking in billions in M & A, despite lingering fears about trade wars and about geopolitics. Transaction values are up almost a fifth this year, a $2.2 trillion, according to data compiled by Bloomberg. The latest boost to activity comes from almost 100 billion worth of deals announced in the U.S. industrial sector alone. Joining us now at the desk, Tom Miles, global co-head of M & A at Morgan Stanley. And the industrial sector was certainly one that has been really exciting. Financials is not too far behind. Where is most of the activity going to be coming from through the course of the year? I think those two sectoral Thank you for having me, Charlie and Matt. I think those two sectors will continue to be drivers of the overall volume has got tailwinds in the financial sector, as you pointed out, deregulation. The benefits of scale really play out in the financial sector. So they will continue to see that sector. We'll continue to see activity as well as industrials. And you've seen it you've seen a lot of activity over the last several weeks as companies have finished up with plans that they've been making over the course of the last several quarters. So what about valuations right now? Because we're not at record highs anymore, but we're pretty close to them. So how do people feel about the price they're paying for assets? What you're seeing is the price that they're paying. They're they're paying good prices for good assets. And so we've seen a number of transactions at what valuations seem high today. But as you go, it just like it's been over the last cycle, when you when the deal works out, the deal works out. So the higher valuations in the public market are certainly not scaring off buyers because most of the activity we're seeing now driven by corporates is highly strategic. So you've got synergies, you've got, you know, greater growth, all those things that, you know, get a company to do M & A are playing out. And so if you pay a price that's reflective of the market, that's what you have to pay to own the asset. Have you seen the kind of deregulation that we were expecting or the light touch regulation that we were expecting at the end of 24, beginning of 25? Well, we've only been a half a year into the new administration. So, yes, you're starting to see that occur. From a tailwind perspective, as I mentioned. So I think you're going to see you've seen a few bank mergers, You've seen a number of very large transactions occur. In fact, transactions over 10 billion through July are up almost 100% globally, up almost 50% in the US. And you saw last week you saw the Union Pacific Act with $85 billion acquisition of Norfolk Southern. Again, in a week where we had $190 billion of transaction value, that's the largest amount of transaction value since November of 2021 in a single week. And so that activity is continuing across all sectors. That's the deal I wanted to ask about specifically, because the idea after President Trump was elected was that we wouldn't have as stringent antitrust regulation. And this is one where you could see it as kind of monopolizing rail in the US or taking a big chunk of it. Do you expect it to go through? I know the companies expect it to go through. Certainly. I think the. Just to step back, I think from an antitrust perspective, I think what what market observers would say is that there is going to be rigorous antitrust enforcement, but with the intention of having the openness to things like remedies. So that wasn't really in existence in the Biden administration. To the extent you have that type of environment, you've got companies allowed to figure out how to get a deal through and how to, you know, propose things that will make it acceptable to the antitrust enforcers. So I think you've got that type of environment and that type of backdrop for a deal like that to happen. Speaking of antitrust, I think it was interesting. Adobe Figma was blocked, right? You had Lina Khan over the weekend and a lot of people pointing out that maybe this was great. At the end of the day, the idea was to keep Figma independent, not let it be acquired by Adobe. It would have been a $20 billion price tag around that deal. Figma Now after the IPO is almost a $50 billion company. So are there some companies here that are looking at what happens and saying, okay, let's stay independent, let's look at an IPO, Let's forget the idea of an M & A in order to get the Figma style treatment. In a good, healthy market, you've got both M & A and IPO alternatives, and that's what we're starting to see. The IPO market, certainly that was a tremendous IPO and we're going to see more of both of those types of transactions in my mind. So, yes, there are some companies that are going to be better off going the IPO route, some companies that are going to choose the M & A route. And that is that is a healthy set of capital markets. I mean, you've got both debt and equity markets are open for business in, you know, in supporting M & A, but also in some. Reporting great companies going public. Our private equity exits have been slow and sparse. Are they going to be able to start doing more M & A so that we have less continuation funds and you know that money? You know, that question is speaking right to my favorite topic. Yes. The monetization of sort of long held private equity assets remains slower than we would all like. And so you've seen an increase in continuation vehicles, minority stake sales. The good thing about it structurally is those will have to happen. And so a better IPO market, a better, you know, capital markets in general, and frankly, was as interest rates ticked down. All those things will help accelerate the monetization that has to happen over the next couple of years. Will it happen in one big spike? Probably not. It'll it'll bleed upwards, I believe, and you'll see that it's a structural benefit to the to the M & A market coming as more private equity owners seek to to monetize. How much pain is there underneath the surface, though, when it comes to private equity, you hear investors talk about the types of returns they're going to get from vintages back to 2018 assets that have been held for a while. It's not looking too pretty based on what investors are saying. So are they are they able to sell these assets at reasonable valuations, at least at par? It's a market, so you have some people doing better than others. What I'd say is that the underlying profitability of the companies is growing over that period of time. So while the return may not look stellar, the multiple of money may get to where they're going to. And that's that's the really the push that the private equity community is trying to to solve for. And I think the you know, we've been through this before. We had the great financial crisis. Different different pockets of time have yielded different returns. And I think we're going to be in one where the facts will say that there's a pocket of lower returns. Probably, you know, they usually precede a pocket of very high return. So it's a it's a it's a it's a set of people that are looking to invest and they continue to invest in large scale. Can you pitch Warren Buffett a deal for his $344 billion in cash? That's a particular criteria. But look, there is from a from a from an acquisition availability perspective, there are lots of great companies out there. You talked in the previous segment about the earnings volatility that's out there that's causing a lot of volatility within individual stocks. And so I think that's another part. As you know, people who have, you know, big piles of cash that are looking to invest, we'll see companies rerate pretty quickly. And so, you know, you have to be on top of that. And I think from our perspective, you know, we see we see M & A opportunities in every pocket of the of the market for for people with large hoards of cash.
